International Journal of Lung Cancer
Издатель: Elsevier · ISSN 3117-504X · 41 статей
- Intraosseous schwannoma of the rib with bone destruction: a case report
- Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients
- Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study
- Definitive diagnosis of pleural mesothelioma by pleural effusion cytology: the MesoCyto study
- Real-world evidence of postoperative adjuvant chemotherapy in patients with stage IA–IIIA non-small cell lung cancer in Japan
- First-line taxane-versus pemetrexed-based chemoimmunotherapy for TTF-1–negative nonsquamous non–small cell lung cancer: a propensity score–matched study
- Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study
- Long-term outcomes of neoadjuvant nivolumab plus chemotherapy in resectable NSCLC in Japanese patients: final 5-year follow-up analysis from CheckMate 816
- First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility
- Real-world comparison of carboplatin–pemetrexed–bevacizumab versus chemo-immunotherapy in EGFR-mutated lung cancer
- Ixazomib enhances the antitumor effect of brigatinib in TP53-mutated EML4-ALK lung cancer cells
- Associations of CBR3 and SLC22A16 Variants with Efficacy and Grade 4 Neutropenia in Relapsed Small-Cell Lung Cancer Treated with Amrubicin
- A comparison of cisplatin plus S-1 versus mitomycin C, vindesine, and cisplatin in concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer: A target trial emulation study using a clinical trial database
- Real-world clinical outcomes of immune checkpoint inhibitors beyond 2 Years in patients with non-small cell lung cancer: A multicenter retrospective study
- Tumor size assessment for prediction of osimertinib efficacy in EGFR-mutated non–small cell lung cancer
- A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)
- Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer
- Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study
- Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with METex14 skipping alterations: a post-marketing surveillance in Japan
- Isoform-specific prognostic value of pleural effusion TGF-β2 in patients with lung cancer
- Utility and limitations of generative artificial intelligence in therapeutic decision-making for advanced lung cancer: a simulation study and questionnaire survey
- Clinical outcomes in early-stage lung cancer with interstitial lung disease: a comparative analysis of stereotactic body radiotherapy and proton beam therapy
- Long-term nationwide post-marketing surveillance cohort study of nivolumab in advanced non-small-cell lung cancer
- Pulmonary combined large-cell neuroendocrine carcinoma with adenocarcinoma and pleomorphic carcinoma components: A case report
- Clinical utility of comprehensive genomic profiling in detecting actionable EGFR exon 20 insertions undetected by companion diagnostics: a case report
- Autoimmune hemolytic anemia following ipilimumab plus nivolumab therapy in a patient with malignant pleural mesothelioma: A case report
- Possible spontaneous regression of lung adenocarcinoma characterized by dense tumor-infiltrating lymphocytes and mature tertiary lymphoid structures: A case report
- Serious abdominal complications during amivantamab-containing therapy in two patients with EGFR-mutated non-small cell lung cancer: case series
- Multiple thymic carcinoids: A case report
- Clinical outcomes and Guardant360 circulating tumor DNA profiling in ALK-positive non-small cell lung cancer treated with lorlatinib after alectinib